Vikaash Kumar

800 total citations
22 papers, 585 citations indexed

About

Vikaash Kumar is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Vikaash Kumar has authored 22 papers receiving a total of 585 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 13 papers in Pulmonary and Respiratory Medicine and 4 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Vikaash Kumar's work include Advanced Breast Cancer Therapies (6 papers), HER2/EGFR in Cancer Research (4 papers) and Cancer Treatment and Pharmacology (3 papers). Vikaash Kumar is often cited by papers focused on Advanced Breast Cancer Therapies (6 papers), HER2/EGFR in Cancer Research (4 papers) and Cancer Treatment and Pharmacology (3 papers). Vikaash Kumar collaborates with scholars based in Canada, United States and Australia. Vikaash Kumar's co-authors include Carolyn J. Peddle‐McIntyre, Neil D. Eves, Mark J. Haykowsky, Tony Reiman, Kerry S. Courneya, Lee W. Jones, Anil A. Joy, Christopher Gray, John R. Mackey and Jagdeep S. Walia and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

Vikaash Kumar

18 papers receiving 573 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Vikaash Kumar Canada	8	309	264	93	85	83	22	585
Arzu Yaren Türkiye	14	283 0.9×	138 0.5×	137 1.5×	88 1.0×	82 1.0×	51	550
C. Seynaeve Netherlands	16	299 1.0×	163 0.6×	52 0.6×	40 0.5×	168 2.0×	37	668
Cecilia Bosco United Kingdom	9	94 0.3×	250 0.9×	102 1.1×	47 0.6×	113 1.4×	23	543
Mark Rochester United Kingdom	14	173 0.6×	120 0.5×	250 2.7×	46 0.5×	110 1.3×	36	602
Donald Poon Singapore	10	314 1.0×	103 0.4×	90 1.0×	25 0.3×	83 1.0×	14	774
Lindsay Carlsson Canada	9	324 1.0×	126 0.5×	73 0.8×	99 1.2×	215 2.6×	25	667
Michelle B. Nadler Canada	12	378 1.2×	161 0.6×	146 1.6×	15 0.2×	85 1.0×	48	651
D.B.Y. Fontein Netherlands	16	454 1.5×	210 0.8×	34 0.4×	45 0.5×	254 3.1×	29	767
David D. Biggs United States	10	231 0.7×	71 0.3×	54 0.6×	47 0.6×	98 1.2×	20	570
Élise Deluche France	16	357 1.2×	111 0.4×	98 1.1×	18 0.2×	108 1.3×	55	670

Countries citing papers authored by Vikaash Kumar

Since Specialization

Citations

This map shows the geographic impact of Vikaash Kumar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vikaash Kumar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vikaash Kumar more than expected).

Fields of papers citing papers by Vikaash Kumar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vikaash Kumar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vikaash Kumar. The network helps show where Vikaash Kumar may publish in the future.

Co-authorship network of co-authors of Vikaash Kumar

This figure shows the co-authorship network connecting the top 25 collaborators of Vikaash Kumar. A scholar is included among the top collaborators of Vikaash Kumar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vikaash Kumar. Vikaash Kumar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Barry, Aisling, Xiang Y. Ye, Peter Chung, et al.. (2025). The role of stereotactic body radiotherapy in oligoprogressive prostate cancer: A site-specific analysis of the prospective, phase II RADIANT trial. Radiotherapy and Oncology. 210. 111041–111041.

Leung, Yvonne, Aman Sidhu, Michelle B. Nadler, et al.. (2025). The Extent to Which Artificial Intelligence Can Help Fulfill Metastatic Breast Cancer Patient Healthcare Needs: A Mixed-Methods Study. Current Oncology. 32(3). 145–145. 3 indexed citations

Pathak, Neha, et al.. (2025). Adverse effect of trastuzumab deruxtecan in solid tumours: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology. 213. 104787–104787. 2 indexed citations

Lajkosz, Katherine, Vikaash Kumar, Di Jiang, et al.. (2025). Survival outcomes for men with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination deficiencies (HRD) treated with radium 223: Princess Margaret Cancer Centre (PMCC) experience. Urologic Oncology Seminars and Original Investigations. 43(11). 665.e1–665.e10.

Cescon, David W., Moira Rushton, Nathalie LeVasseur, et al.. (2025). IND.241: A Canadian Cancer Trials Group liquid-biopsy informed platform trial to evaluate treatment in CDK4/6-inhibitor resistant ER+/HER2- metastatic breast.. Journal of Clinical Oncology. 43(16_suppl). 1 indexed citations

Kumar, Vikaash, et al.. (2025). Efficacy and Safety of Metastatic Directed Treatment of Oligometastatic Disease: Results of a Meta-analysis. Advances in Radiation Oncology. 10(7). 101797–101797. 1 indexed citations

Mittal, Abhenil, Zachary Veitch, Vikaash Kumar, et al.. (2024). The Survival Outcomes of the Metastatic Nonclear Cell Renal Cell Carcinoma in the Immunotherapy Era: Princess Margaret Cancer Centre Experience. SHILAP Revista de lepidopterología. 11(1). 41–48. 2 indexed citations

Elliott, Mitchell J., et al.. (2024). Comparative overall survival of CDK4/6 inhibitors in combination with endocrine therapy in advanced breast cancer. Scientific Reports. 14(1). 3129–3129. 19 indexed citations

Hueniken, Katrina, Nimira Alimohamed, Nazanin Fallah‐Rad, et al.. (2024). Real-world evidence for enfortumab vedotin (EV) in metastatic urothelial carcinoma (mUC): a multi-centred observational study in a publicly funded Canadian system.. Journal of Clinical Oncology. 42(16_suppl). e16566–e16566.

10.

Pathak, Neha, Efthymios Papadopoulos, Vikaash Kumar, & Shabbir M.H. Alibhai. (2024). Frailty in Older Adults with Prostate Cancer. European Urology Oncology. 8(1). 14–20. 1 indexed citations

11.

Jiang, Di, Nazanin Fallah‐Rad, Philippe L. Bédard, et al.. (2023). A retrospective review of primary prophylaxis with granulocyte-colony stimulating factor (G-CSF) for patients with genitourinary malignancies receiving chemotherapy during the COVID-19 pandemic and implications for the future.. Journal of Clinical Oncology. 41(6_suppl). 115–115. 1 indexed citations

12.

Elliott, Mitchell J., et al.. (2023). Comparative overall survival of patients in trials of CKD4/6 inhibitors in combination with endocrine therapy in advanced breast cancer.. Journal of Clinical Oncology. 41(16_suppl). 1056–1056. 1 indexed citations

13.

Cescon, David W., John Hilton, Philippe L. Bédard, et al.. (2023). Abstract P3-07-14: A phase II study of CFI-400945 in patients with advanced/metastatic cancer: Canadian Cancer Trials Group (CCTG) IND.237. Cancer Research. 83(5_Supplement). P3–7.

14.

Desnoyers, Alexandra, Michelle B. Nadler, Vikaash Kumar, Ramy Saleh, & Eitan Amir. (2020). Comparison of treatment-related adverse events of different Cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer: A network meta-analysis. Cancer Treatment Reviews. 90. 102086–102086. 51 indexed citations

15.

Gray, Christopher, et al.. (2018). PARP Inhibitor Drugs in the Treatment of Breast, Ovarian, Prostate and Pancreatic Cancers: An Update of Clinical Trials. Current Drug Targets. 19(1). 21–37. 99 indexed citations

16.

Chia, Stephen, Susan Ellard, Mihaela Mates, et al.. (2017). A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer. Breast Cancer Research. 19(1). 54–54. 32 indexed citations

17.

Hotte, Sébastien J., Elizabeth A. Eisenhauer, Anthony M. Joshua, et al.. (2013). NCIC CTG, IND-205: A phase II study of PX-866 in patients with recurrent or metastatic castration-resistant prostate cancer (CRPC).. Journal of Clinical Oncology. 31(15_suppl). 5042–5042. 6 indexed citations

18.

Kumar, Vikaash, Mustaq Khan, George A. Vilos, & Verinder Sharma. (2011). Revisiting the Association Between Endometriosis and Bipolar Disorder. Journal of Obstetrics and Gynaecology Canada. 33(11). 1141–1145. 21 indexed citations

19.

Jones, Lee, Neil D. Eves, Carolyn J. Peddle‐McIntyre, et al.. (2009). Effects of presurgical exercise training on systemic inflammatory markers among patients with malignant lung lesions. Applied Physiology Nutrition and Metabolism. 34(2). 197–202. 51 indexed citations

20.

Jones, Lee W., Carolyn J. Peddle‐McIntyre, Neil D. Eves, et al.. (2007). Effects of presurgical exercise training on cardiorespiratory fitness among patients undergoing thoracic surgery for malignant lung lesions. Cancer. 110(3). 590–598. 252 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact